PHARMACEUTICAL 2022

China Pharma Holdings INC
Rank 361 of 471



PHARMACEUTICAL 2022

China Pharma Holdings INC
Rank 361 of 471

The relative strengths and weaknesses of China Pharma Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of China Pharma Holdings INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 64% points.The greatest weakness of China Pharma Holdings INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 87% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	9,093
Cost of Goods Sold	9,293
Intangible Assets	148
Liabilities, Current	10,513
Liabilities, Non-Current	44
Other Assets	128
Other Compr. Net Income	218
Other Expenses	1,240
Other Liabilities	6,074
Other Net Income	-539
Other Revenues	9,642
Property and Equipment	13,281
Research and Development	319
Selling, General and Administrative Expense	1,651

Output Variable	Value in 1000 USD
Assets	22,650
Liabilities	16,632
Expenses	12,502
Revenues	9,642
Stockholders Equity	6,018
Net Income	-3,399
Comprehensive Net Income	-3,290
BaseVar	31,092
ECR before LimitedLiability	50%
Economic Capital Ratio	188%